Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To assess the safety and toxicity of imatinib mesylate when given to patients with Ph (+)
CML , ALL or AML within the first 100 days following allogeneic bone marrow or stem cell
transplantation.
Secondary Objectives:
1. To identify any clinically significant drug interactions with imatinib in the
post-transplant setting.
2. To develop specific monitoring parameters for imatinib use when utilized in the early
post-BMT setting.
3. To record one-year survival data in this patient cohort to assess any effect of early
imatinib administration on this endpoint.